Aspirin, Salicylates and Cancer

ASPIRIN, SALICYLATES AND CANCER Organised by the Aspirin Foundation - Sponsored by Bayer Schering Pharma AG Marcus Beck Library, Royal Society of Medicine, Wimpole Street, London W1 Tuesday 23rd November 2010 PROGRAMME 11.00 Coffee in Marcus Beck Library

11.15 CHAIR: Professor Peter Elwood Department of Epidemiology, College of Medicine, Cardiff University Opening remarks Dr Gareth Morgan Project Manager for Older People’s Services, NHS Wales A brief summary of all cancer conditions

11.50 Professor Peter Rothwell Professor of Clinical Neurology, University of Oxford Effects on colorectal cancer risk in randomised trials of Aspirin

12.20 Professor Sir John Burn Professor of Clinical Genetics, Newcastle University Aspirin in the prevention and treatment of colorectal cancer

12.50 Press Briefing

13.15 Lunch served in the ENT Room (ground floor)

14.15 Professor Andrew Chan Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston Mode of action and dosage

14.35 Dr Luis Mur Deputy Leader of Bio-renewables & Environmental Change Research Division, Aberystwyth University Salicylate salts in plants

14.55 Professor Dion Morton Professor of Colorectal Surgery, University of Birmingham Colon cancer screening programmes and the place for Aspirin

15.15 Tea break in Marcus Beck Library

15.30 Professor Jack Cuzick Cancer Research UK Centre for Epidemiology, Mathematics & Statistics, London Aspirin and other NSAIDs for cancer prevention

15.50 Dr Elmar Detering Global Medical Affairs Physician (CardioAspirin) Bayer Schering Pharma AG A short overview from BSP meeting of experts, October 2010 in Berlin

16.10 Professor Gordon McVie, Senior Consultant, Instituto Europeo di Oncologia, Italy/ General Discussion - Contributions from all participants

17.30 Bayer / CompaniesClose of havemeeting no influence on agenda or content of the Aspirin Foundation meeting